Analytical Data
-
Gene name
ETV6
- Application
-
Alternative Names
TEL; TEL1
-
Species
Human
-
Source
E. coli
-
Tag
Strep;His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41212
-
Expression Region
C338-E451
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ETV6 (ETS variant 6) is a transcription factor that plays a critical role in hematopoiesis and the regulation of various developmental processes. Research on ETV6 has gained significant attention due to its involvement in several hematological malignancies, particularly in the context of chromosomal translocations that result in ETV6 fusion proteins. The most notable of these is the ETV6/RUNX1 fusion, which is commonly associated with childhood acute lymphoblastic leukemia (ALL). This fusion gene leads to the dysregulation of normal hematopoietic differentiation and proliferation, implicating ETV6 as a crucial player in the pathogenesis of leukemia. Additionally, ETV6 has been implicated in other cancers, such as breast cancer and solid tumors, suggesting its broader relevance in oncology. Understanding the molecular mechanisms by which ETV6 and its fusion proteins contribute to tumorigenesis can provide insights into potential therapeutic targets. Ongoing research aims to elucidate the pathways regulated by ETV6, the functional consequences of its mutations, and the potential for utilizing ETV6-related biomarkers in early diagnosis and treatment stratification for patients with related malignancies. Overall, the study of ETV6 and its associated proteins holds promise for developing targeted therapies and improving clinical outcomes in cancer treatment.
